• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Quick Take: Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042)

byKyle HoffmanandAliya Ramjaun
April 11, 2019
in Chronic Disease, Oncology, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]

The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

Pembrolizumab is a monoclonal antibody against programmed cell death protein 1 (PD-1). Previous studies have shown that pembrolizumab is effective in prolonging survival in advanced non-small-cell lung cancer (NSCLC) with a PD1-ligand (PD-L1) tumor proportion score (TPS) of 50% or greater. In this randomized, open-label, phase 3 study, pembrolizumab was investigated for its efficacy in prolonging survival in locally advanced or metastatic NSCLC with a PD-L1 TPS of 1% or greater. Patients were included in the study if they had previously untreated locally advanced or metastatic NSCLC, expressed PD-L1 as above, had an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1, and did not have a sensitizing EGFR mutation or ALK translocation (n=1,274).  They were randomized to receive either pembrolizumab (200 mg every 3 weeks for up to 35 cycles) or the investigator’s choice of platinum-based chemotherapy (4-6 cycles). Analysis was performed on three separate groups, those with PD-L1 TPS of 50% or greater, 20% or greater, and 1% or greater. Researchers found that pembrolizumab prolonged overall survival in all three analyses, as compared to chemotherapy, yielding a hazard ratio for death of 0.69 in those with 50% or greater PD-L1 TPS (95% CI 0.56 to 0.85, p=0.0003), 0.77 in those with 20% or greater PD-L1 TPS (95% CI 0.64 to 0.92, p=0.0020), and 0.81 in those with 1% or greater PD-L1 TPS (95% CI 0.71 to 0.93, p=0.0018). Treatment-related adverse events that were grade 3 or higher were significantly less common in the pembrolizumab group (18%), as compared to the chemotherapy group (41%). Similar treatment-related death rates occurred. Investigators therefore concluded that pembrolizumab is an effective first-line therapy in patients with metastatic or locally advanced NSCLC with greater than 1% PD-L1 TPS who do not have other sensitizing mutations or translocations.

Click to read the study in Lancet

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: monoclonal antibodynon-small cell lung cancer (NSCLC)Pembrolizumabprogrammed cell death protein 1 (PD-1)
Previous Post

#VisualAbstract: Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients

Next Post

Quick Take: Effect of a Multifaceted Quality Improvement Intervention on the Prescription of Evidence-Based Treatment in Patients at High Cardiovascular Risk in Brazil

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]

July 2, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]

July 1, 2022
#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients
StudyGraphics

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

June 30, 2022
Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients
Oncology

High tumour mutation burden in NSCLC associated with improved clinical outcomes of PD-L1 blockade across PD-L1 expression subgroups

June 27, 2022
Next Post
Prevalence of hypertension among adolescents varies by race and BMI

Quick Take: Effect of a Multifaceted Quality Improvement Intervention on the Prescription of Evidence-Based Treatment in Patients at High Cardiovascular Risk in Brazil

#VisualAbstract: Randomized Trial of Platelet-Transfusion Thresholds in Neonates

#VisualAbstract: Randomized Trial of Platelet-Transfusion Thresholds in Neonates

Sofosbuvir-velpatasvir shows promise in HCV genotype 2 and 3 infection: The ASTRAL 2-3 study

HCV-positive heart and lung transplant likely safe with post-transplant sofosbuvir-velatasivir treatment

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.